Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 re-activator tested in combination with azacitidine in maintenance post-HSCT in TP53 mutated (TP53m) AML or MDS. The gene discussed is TP53; the disease is acute myeloid leukemia.